Strong Heart Study

NCT ID: NCT00005134

Last Updated: 2016-07-29

Basic Information

• Recruitment Status: COMPLETED
• Study Classification: OBSERVATIONAL
• Study Start Date: 1988-09-30
• Study Completion Date: 2005-12-31

Brief Summary

To determine morbidity and mortality from cardiovascular disease among American Indians and to compare cardiovascular disease risk factor levels among Indian groups living in different geographic areas.

Detailed Description

BACKGROUND:

Available data indicate that cardiovascular disease has become the leading cause of death in American Indians. Some Indian groups appear to be participating in the decline in cardiovascular disease rates occurring within the overall United States population, but, among other Indians, rates appear to be increasing. In addition, there appears to be excessive mortality attributed to cardiovascular disease in younger Indians.

Several problems have made it difficult to obtain adequate data on the prevalence and severity of cardiovascular disease as a health problem among American Indians. The small size, relatively young age, cultural and anthropological diversity and the geographic dispersion of the American Indian population have made it impractical to examine large numbers of subjects for research and vital statistics surveys. Excess mortality among younger Indians from noncardiovascular causes may have obscured the true risk of cardiovascular disease in this population. Definitions of the term 'Indian' are variable in published reports. The denominators from which disease rates were calculated often were based on uncertain estimates of the population at risk. Definitions of disease and methods of its ascertainment have varied in different studies. In addition, health care services available to Indians vary considerably in different geographic areas, and possibly contribute to differences in reported morbidity and mortality.

States with the largest Indian populations are Arizona, Oklahoma, California, New Mexico and North Carolina. Because the major concentrations of Indian tribal groups in the United States are located in the Southwest, more than half of the reported studies of cardiovascular disease and cardiovascular disease risk factors have been conducted in these groups. Studies have been reported in the Pima, Papago, Navajo, Apache, Hopi and other tribes in the Arizona and New Mexico region. In general, these studies have concluded that cardiovascular disease rates are lower in these Indian groups than in the United States population.

The etiology, manifestations and natural history of cardiovascular disease among Indians are not well known. Current information indicates 43 percent of heart disease deaths among Native Americans are secondary to myocardial infarction and 32 percent are due to chronic ischemic heart disease. Below the age of 35 years, the heart disease death rate in Native Americans exceeded reported United States rates. A significant portion of this excess may be due to congenital heart disease.

Limited data are available on current levels and time related changes in risk factors for ischemic cardiovascular disease among American Indians. Because of the absence of systematic surveys of defined populations and the lack of standardization of methodology employed in studies of different groups, it is difficult to interpret apparent increases in risk factors over time or to explain apparent differences in cardiovascular disease rates by differences in risk factor distributions. Studies of current risk factor levels and distributions are of great importance, however, since they may provide the best estimates of the future relative risk of cardiovascular disease within the Indian population.

Multiple factors may contribute to current risk factor levels in American Indians. Variations may exist among tribal groups, secondary to genetic admixture and to both the degree and duration of acculturation and in relation to attained socioeconomic status. It is important to recognize that generalizations about risk factors for cardiovascular disease in American Indians are inappropriate and that available data only apply to groups with similar origins and history.

The study was recommended by the Subcommittee on Cardiovascular and Cerebrovascular Disease of the Secretary of Health and Human Services Task force on Black and Minority Health in 1986 and was approved by the National Heart, Lung, and Blood Advisory Council in May 1987. The Request for Applications was released in October 1987 with awards made in September 1988. The study was renewed and expanded twice.

DESIGN NARRATIVE:

The study is conducted on defined populations of Indians living on reservations and involves two components: a review of death certificates and health care records: and a population survey of the prevalence of and risk factors for cardiovascular disease. The population survey phase consists of three examinations for cardiovascular disease risk factors, clinical cardiac disease, and the use of medical services for cardiovascular disease care. Elisa Lee of the University of Oklahoma is studying members of the seven tribes of Oklahoma. Thomas Welty at the Aberdeen Area Indian Health Service follows three Northern Sioux tribes. Barbara Howard of Medlantic studies Pima Indians from the Gila River and Salt River Indian communities.

After the initial three years the Strong Heart Study was renewed to: extend surveillance of the community for mortality; and to reexamine the cohort after an approximate four year interval to assess the development of cardiovascular disease and change in CVD risk factors. Echocardiography and pulmonary function testing were added to the examination protocol for the second examination. In 1996 the study was funded to continue the follow-up for morbidity and mortality and to complete a third examination of the study cohort. New measures added to the third exam included measures of carotid atherosclerosis, arterial stiffness, a substudy of asthma, and a family study pilot. The third examination of the cohort was completed in August, 1999 with 3,200 members reexamined. In addition, more than 560 participants were included in the substudy of asthma. There have been approximately 1,000 deaths among cohort members in the 12 years since the initial examination.

Phase IV of the study began in FY 2000 for a five-year extension to expand the family study and to continue morbidity and mortality surveillance of the original cohort. Each of the three field centers will recruit an additional 900 participants who are members of families containing at least two SHS cohort members. Furthermore, the pilot study family members will be invited to a follow-up exam after the 900 members are enrolled at each center. The Phase IV family study exams will include cardiac and carotid ultrasound exams, blood pressures, noninvasive measurements of arterial stiffness (tonometry), ECGs, anthropometry, medical history, behavioral assessments (socio-economic status, diet, smoking, alcohol, and physical activity), blood chemistries, lipids, and DNA. The specific aims of the Phase IV study are to expand the family study to increase the power for genetic analyses, to continue surveillance of the original cohort to ascertain more CVD cases, to investigate the association of some pertinent biomarkers and cardiac functions with the development of CVD, and to initiate mortality surveillance in the family members.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provided funding for a gallstone component.

Conditions

Cardiovascular Diseases; Heart Diseases; Atherosclerosis; Asthma; Carotid Artery Diseases; Coronary Disease; Hypercholesterolemia; Hypertension; Diabetes Mellitus; Obesity

Eligibility Criteria

Inclusion Criteria

No eligibility criteria

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: lead

Principal Investigators

Lyle Best

Role:

U.S. P.H.S. Aberdeen Area Indian Health Services

Richard Devereux

Role:

Weill Medical College of Cornell University

Barbara Howard

Role:

Medlantic Research Foundation

Elisa Lee

Role:

University of Oklahoma

Jean MacCluer

Role:

Southwest Foundation for Biomedical Research

References

Please refer to the Strong Heart Study Home Page for complete bibliography. http://strongheart.ouhsc.edu/

Reference Type: BACKGROUND

Fretts AM, Jensen PN, Sitlani CM, Hoofnagle A, Lidgard B, Umans JG, Siscovick DS, King IB, Howard BV, Cole SA, Lemaitre RN. Circulating Sphingolipids and All-Cause Mortality: The Strong Heart Family Study. J Am Heart Assoc. 2024 Jul 2;13(13):e032536. doi: 10.1161/JAHA.123.032536. Epub 2024 Jun 21.

Reference Type: DERIVED

PMID: 38904223 (View on PubMed)

Fretts AM, Jensen PN, Hoofnagle A, McKnight B, Howard BV, Umans J, Yu C, Sitlani C, Siscovick DS, King IB, Sotoodehnia N, Lemaitre RN. Plasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study. J Nutr. 2020 May 1;150(5):1214-1222. doi: 10.1093/jn/nxz259.

Reference Type: DERIVED

PMID: 31665380 (View on PubMed)

Mancusi C, de Simone G, Best LG, Wang W, Zhang Y, Roman MJ, Lee ET, Howard BV, Devereux RB. Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the Strong Heart Study cohort. Cardiovasc Diabetol. 2019 Apr 30;18(1):56. doi: 10.1186/s12933-019-0862-9.

Reference Type: DERIVED

PMID: 31039789 (View on PubMed)

Lemaitre RN, Yu C, Hoofnagle A, Hari N, Jensen PN, Fretts AM, Umans JG, Howard BV, Sitlani CM, Siscovick DS, King IB, Sotoodehnia N, McKnight B. Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study. Diabetes. 2018 Aug;67(8):1663-1672. doi: 10.2337/db17-1449. Epub 2018 Mar 27.

Reference Type: DERIVED

PMID: 29588286 (View on PubMed)

de Simone G, Wang W, Best LG, Yeh F, Izzo R, Mancusi C, Roman MJ, Lee ET, Howard BV, Devereux RB. Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol. 2017 May 12;16(1):64. doi: 10.1186/s12933-017-0542-6.

Reference Type: DERIVED

PMID: 28499385 (View on PubMed)

Related Links

http://strongheart.ouhsc.edu/

Related Info

Other Identifiers

U01HL065520

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1004

Identifier Type: -

Identifier Source: org_study_id